5 Key Takeaways
-
1
NCX 470, an investigational drug by Nicox, showed favorable results compared to latanoprost in a post hoc analysis of the Mont Blanc trial.
-
2
The analysis indicated a statistically significant greater proportion of eyes treated with NCX 470 achieved IOP of ≤18 mmHg.
-
3
NCX 470 combines bimatoprost effects with nitric oxide to enhance aqueous humor outflow for treating open-angle glaucoma.
-
4
While the Mont Blanc trial did not meet all secondary efficacy endpoints, NCX 470 was numerically superior at all time points.
-
5
Nicox plans to file a New Drug Application with the FDA in 2026, with ongoing evaluations in the Denali and Whistler trials.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.